These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
611 related articles for article (PubMed ID: 31799745)
1. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens. Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745 [TBL] [Abstract][Full Text] [Related]
2. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. Begemann D; Wang Y; Yang W; Kyprianou N Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812 [TBL] [Abstract][Full Text] [Related]
3. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822 [TBL] [Abstract][Full Text] [Related]
4. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342 [TBL] [Abstract][Full Text] [Related]
5. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Liu C; Armstrong C; Zhu Y; Lou W; Gao AC Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719 [TBL] [Abstract][Full Text] [Related]
6. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698 [TBL] [Abstract][Full Text] [Related]
7. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Tummala R; Nadiminty N; Lou W; Evans CP; Gao AC Prostate; 2016 Apr; 76(5):445-55. PubMed ID: 26714839 [TBL] [Abstract][Full Text] [Related]
8. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299 [TBL] [Abstract][Full Text] [Related]
9. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Lombard AP; Liu L; Cucchiara V; Liu C; Armstrong CM; Zhao R; Yang JC; Lou W; Evans CP; Gao AC Mol Cancer Ther; 2018 Oct; 17(10):2197-2205. PubMed ID: 29891490 [TBL] [Abstract][Full Text] [Related]
10. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor. Patki M; Huang Y; Ratnam M Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779 [TBL] [Abstract][Full Text] [Related]
12. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198 [TBL] [Abstract][Full Text] [Related]
13. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141 [TBL] [Abstract][Full Text] [Related]
14. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model. Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672 [TBL] [Abstract][Full Text] [Related]
15. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Gaur S; Gross ME; Liao CP; Qian B; Shih JC Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539 [TBL] [Abstract][Full Text] [Related]
16. Downregulation of Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112 [TBL] [Abstract][Full Text] [Related]
17. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy. Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence. Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834 [TBL] [Abstract][Full Text] [Related]